

---

## Literatura

---

1. Abbey, S. E., Garfinkel, P. E.: Neurasthenia and chronic fatigue syndrome: the role of culture in the making of a diagnosis. *American Journal of Psychiatry* 1991, 148: 35–53.
2. Afari, N., Buchwald, D.: Chronic fatigue syndrome: a review. *American Journal of Psychiatry* 2003 Feb;160 (2): 221–236.
3. Barker, E. et al.: Immunologic abnormalities associated with chronic fatigue syndrome. *Clinical Infect. Dis.* 1994, 18: 136–141.
4. Baštecký, J. et al.: *Psychosomatická medicína*. Praha, Grada-Avicenum, 1993.
5. Bebbington et al.: Neurotic disorders and the receipt of psychiatric treatment *Psychol. Med.* 2000; 30: 1369–1376.
6. Blackwood, S. K., Mac Hale, S. M., Power, M. J. et al.: Effects of exercise on cognitive and motor function in chronic fatigue syndrome and depression. *J. Neurol. Neurosurg. Psychiatry (England)* 1998; 65 (4): 541–546.
7. Blondel-Hill, E., Shafran, S. D.: Treatment of the Chronic Fatigue Syndrome. A Review and Practical Guide. *Drugs* 1993, 46: 639–651.
8. Brosschot, J. F. et al.: Influence of life stress on immunological reactivity to mild psychological stress. *Psychosom. Medicine* 1994, 56: 216–224.



9. Brouwers, F. M.: The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: a double-blind randomized controlled trial. *QJM* 2002 Oct; 95 (10): 677–683.
10. Buchwald, D., Komaroff, A. L.: Review of laboratory findings for patients with chronic fatigue syndrome. *Review of Infectious Diseases* 1991, 13, suppl. 1: 12–18.
11. Buchwald, D.: Fibromyalgia and chronic fatigue syndrome: similarities and differences. *Rheum. Dis. Clinical of North America* 1996, 22: 219–243.
12. Buchwald, D. et al.: Frequency of „chronic active Epstein-Barr virus infection“ in a general practice. *JAMA* 1987, 257: 2303–2307.
13. Buskila, D.: Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. *Curr. Opin. Rheumatol.* 2000; 12 (2): 113–123.
14. Butler, S. et al.: Cognitive behaviour therapy in chronic fatigue syndrome. *Journal of Neurology, Neurosurgery and Psychiatry* 1991, 54: 153–158.
15. Caligiury, M. et al.: Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. *Journal of Immunology* 1987 Nov. 15, 139 (10): 3306–3313.
16. Carter, R. E.: Chronic intestinal candidiasis as a possible etiological faktor in the chronic fatigue syndrome. *Medical Hypotheses* 1995, 44: 507–515.
17. Cattell, R.: Šestnáctifaktorový dotazník, 16 PF. Psychodiagnostické a didaktické testy, n. p. Bratislava 1975: 122.
18. Chrousos, G. P., Gold, P. W.: The concept of stress and stress system disorders: Overview of physical and behavioral homeostasis, *JAMA* 1992, 267: 1244–1252.
19. Cox, I. M. et al.: Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 1991, 337: 757–760.
20. Dwyer, J. M.: Immunological disturbances in patients with the chronic fatigue syndrome. *Immunol. Updates* 1992, 3: 1–6.
21. Englebienne, P. et al.: Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. *Med. Hypotheses* 2003 Feb; 60 (2): 175–180.
22. Evengard, B., Schacterle, R. S., Komaroff, A. L.: Chronic fatigue syndrome: new insights and old ignorance. *J. Intern. Med.* 1999; 246 (5): 455–469.
23. Evengard, B., Klimas, N.: Chronic fatigue syndrome: probable pathogenesis and possible treatments. *Drugs* 2002, 62 (17): 2433–2446.
24. Farmer, A. et al.: Neurasthenia revisited: ICD-10 and DSM-III-R psychiatric syndromes in chronic fatigue patients and comparison subject. *British Journal of Psychiatry* 1995, 167: 503–506.
25. Ferenčík, M., Štvrtinová, V.: Základné vzťahy a prepojenia medzi imunitným, nervovým a endokrinným systémom. *Klinická imunológia a alergológia* 1998: 16–22.
26. Filip, V., et al.: Praktický manuál psychiatrických posuzovacích stupnic. Praha 1997. Psychiatrické centrum Praha, 214 s.
27. Fricchione, G. L., Stefano, G. B.: The stress response and autoimmunoregulation. *Advances in Neuroimmunology* 1994, 4: 13–27.
28. Friedberg, F., Krupp, L. B.: A comparison of cognitive behavioral treatment for chronic fatigue syndrome and pri-



- mary depression. *Clinical Infect. Dis.* 1994, 18, suppl. 1: 105–110.
29. Fučíková, T.: *Klinická imunologie v praxi*. Praha. Galén 1997: 108–115,
30. Fukuda, K. et al.: The chronic fatigue syndrome: A comprehensive approach to its definition and study. *Ann. Intern. Med.* 1994, 121: 953–959.
31. Gaab, J. et al.: Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological and pharmacological stimulation. *Psychosom. Med.* 2002 Nov-Dec; 64 (6): 951–962.
32. Goodnick, P. J., Dandoval, R.: Psychotropic treatment of chronic fatigue syndrome and related disorders. *Journal of Clinical Psychiatry* 1993, 54: 13–20.
33. Goodnick, P. J.: Bupropion in chronic fatigue syndrome. *American Journal of Psychiatry*, 147, 1990, s.
34. Goodnick, P. J. et al.: Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. *Biological Psychiatry* 1992, 56: 834–838.
35. Goroll, A. H., May, L. A., Mulley, A. G.: *Primary Care Medicine: Office Evaluation and Management of the Adult Patient*. 3<sup>rd</sup> Edition, JB. Lippincott, Philadelphia, USA 1995.
36. Gray, J. B., Martinovic, A. M.: Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome. *Medical Hypotheses* 1994, 43: 31–42.
37. Greco, A. et al.: Brain MR in chronic fatigue syndrome. *Am. Journal of Neuroradiology* 1997, 18: 1265–1269.
38. Gupta, A.: Unconscious amygdalar fear conditioning in a subset of chronic fatigue syndrome patients. *Med. Hypotheses* 2002 Nov; 59 (6): 727–735.
39. Hellinger, W. C. et al.: Chronic fatigue syndrome and the diagnostic utility of antibody to Epstein-Barr virus early antigen. *Journal of American Medical Association* 1988, 260: 971–973.
40. Hoffmann, A., Linder, R., Kroger, B. et al.: Fibromyalgie-Syndrom und Chronic-Fatigue-Syndrom. Gemeinsamkeiten und Unterschiede. *Dtsch. Med. Wochenschr* 1996, 121 (38): 1165–1168.
41. Holmes, G. P. et al.: Chronic fatigue syndrome: a working case definition. *Annals of Internal Medicine* 1988, 108: 387–389.
42. Holmes, G. P.: Working definition of chronic fatigue syndrome. *Rev. Infect. Dis.* 1991; 13: 53.
43. Höschl, C.: *Psychiatrie pro praktické lékaře*. Praha, H+H 1996, 94 s.
44. Höschl, C.: *Neuroendokrinologie v psychiatrii*. Praha, Avicenum 1989, 321 s.
45. Chaudhuri, A. et al.: Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. *Neuroreport* 2003 Feb 10; 14 (2): 225–228.
46. James, L. C., Polen, R. A.: EEG biofeedback as a treatment for chronic fatigue syndrome: a controlled case report. *Behavioral Medicine* 1996, 22: 77–81.
47. Janu, L., Sumcovova, P.: Diagnostické a terapeutické algoritmy chronického únavového syndromu. *Psychiatrie pro praxi* 2002, 5: 205–206.
48. Jason, L. A. et al.: Estimating the prevalence of chronic fatigue syndrome among nurses. *Am. J. Med. (United States)* 1998; 105 (3A): 91–93.
49. Johnson, S. K. et al.: Assessing somatization disorder with the chronic fatigue syndrome. *Psychosomatic Medicine* 1996, 58: 50–57.



50. Jones, J. F. et al.: Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. *Annals of Internal Medicine* 1985, 102: 1–7.
51. Kang, H. K. et al.: Post-traumatic stress disorder and chronic fatigue syndrome-like illness among Gulf War veterans: a population-based survey of 30 000 veterans. *Am. J. Epidemiol.* 2003 Jan. 15, 157 (2): 141–148.
52. Kroenke, K. et al.: Chronic fatigue in primary care. *JAMA* 1988, 260: 929–934.
53. Kruesi, M. J. P. et al.: Psychiatric diagnoses in patients who have chronic fatigue syndrome. *Journal of Clinical Psychiatry* 1993, 50: 53–56.
54. Lane, R. M.: Aetiology, diagnosis and treatment of chronic fatigue syndrome. *Journal of Serotonin Research* 1994, 1: 47–60.
55. Lane, R., M.: Potenciál farmakologických lékových interakcí selektivních inhibitorů zpětného vychytávání serotoninu. *International Clinical Psychopharmacology* 1996, 11: 31–61.
56. Lehman, A. M.: Illness experience, depression and anxiety in chronic fatigue syndrome. *J. Psychosom. Res.* 2002 Jun., 52 (6): 461–465.
57. Lerner, A. M. et al.: A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. *Drugs Today (Barc.)* 2002 Aug. 38 (8): 549–561.
58. Levine, P. H.: The use of transfer factor in chronic fatigue syndrome: prospects and problems. *Biotherapy* 1996, 9: 77–79.
59. Lloyd, A. R. et al.: Immunity and the pathophysiology of chronic fatigue syndrome. In *Chronic Fatigue Syndrome*. G. R. Bock and J. Whelan, 1993: 176–192.
60. Lloyd, A. R.: Immunologic and Psychologic Therapy for Patients With Chronic Fatigue Syndrome: A Double-Blind, Placebo Controlled Trial. *The American Journal of Medicine* 1993, 94: 197–203.
61. De Lorenzo, F. et al.: Pathogenesis and management of delayed orthostatic hypotension in patient with chronic fatigue syndrome. *Clinical Auton. Res.* 1997, 7: 185–190.
62. Van de Luit, L. et al.: Amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome: improvement by inopamil but not by melatonin. *Angiology* 1998, 49: 903–908.
63. Manu, P. et al.: Chronic fatigue syndrome: clinical epidemiology and etiological classification. *Chronic fatigue syndrome*. G. R. Bock and J. Whelan 1993: 23–42.
64. Masuda, A.: The prognosis after multidisciplinary treatment for patients with postinfectious chronic fatigue syndrome and noninfectious chronic fatigue syndrome. *J. Behav. Med.* 2002 Oct. 25 (5): 487–497.
65. Masuda, A.: Psychosocial characteristics and immunological functions in patients with postinfectious chronic fatigue syndrome and noninfectious chronic fatigue syndrome. *J. Behav. Med.* 2002 Oct. 25 (5): 477–485.
66. McCauley, L. A. et al.: Chronic fatigue in a population-based study of Gulf War veterans. *Arch Environ Health* 2002 Jul.-Aug. 57 (4): 340–348.
67. McCully, K. K. et al.: Blood flow and muscle metabolism in chronic fatigue syndrome. *Clin. Sci. (Lond)* 2003 Feb 18.



68. McKanzie, R. et al.: Low-dose hydrocortizone for treatment of chronic fatigue syndrome: a randomized controlled trial. *JAMA* 1998, 280: 1061–1066.
69. Morris, D. H., Stare, F. J.: Unproven diet therapies in the treatment of the chronic fatigue syndrome. *Archives of Fam. Medicine* 1993, 2: 181–186.
70. Müller, L.: Únava – daň za úspěch? *Propsy* 1998, 4: 8–9.
71. Naschitz, J. E. et al.: The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. *Q. J. M.* 2003 Feb. 96 (2): 133–142.
72. Natelson, B. H. et al.: Single blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. *Neuropsychobiology* 1998, 37: 150–154.
73. Natelson, B. H. et al.: Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. *Psychopharmacology* 1996, 124: 226–230.
74. Nouza, M., Svoboda, J.: *Chronický únavový syndrom*. Praha, Galén 1998.
75. Olson, L. G. et al.: A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. *Psychosomatics* 2003 Jan.-Feb. 44 (1): 38–43.
76. Parlante, C. M., Miller, A. H.: Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylinipramine treatment. *European Neuropsychopharmacology* 1995, 5, suppl.: 83–88.
77. Peakman, M. et al.: Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. *Clin. Immunol. Immunopathol.* 1997, 82: 83–91.
78. Peterson, P. K. et al.: A controlled trial of intravenous im-

- munoglobulin G in chronic fatigue syndrome. *American Journal of Medicine* 1990, 89: 554–560.
79. Plioplys, A. V., Plioplys, S.: Amantadin and L-carnitine treatment of Chronic Fatigue syndrome. *Neuropsychobiology* 1997, 35: 16–23.
80. Razumovsky, A. Y. et al.: Cerebral and systemic hemodynamics changes during upright tilt in chronic fatigue syndrome. *J. Neuroimaging* 2003 Jan. 13 (1): 57–67.
81. Reid, S., Chalder, T., Cleare, A. et al.: Chronic fatigue syndrome. *B. M. J.* 2000, 320 (7230): 292–296.
82. Richter, J. et al.: Syndrom mnohočetné chemické přecitlivělosti a chronický únavový syndrom – podobnost čistě náhodná? *Prakt. lékař.* 1996, 76: 16–19.
83. Schmaling, K. B. et al.: Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. *Psychosom. Med.* 2003 Jan.-Feb. 65 (1): 129–136.
84. See, D. M., Tilles, J. G.: Alpha-Interferon treatment of patients with chronic fatigue syndrome. *Immunol. Invest.* 1996, 25: 153–164.
85. Shanks, M. F., Ho-Yen D. O.: A clinical study of chronic fatigue syndrome. *British Journal of Psychiatry* 1995, 166: 798–801.
86. Sharpe, M.: Chronic fatigue syndrome. *Psychiatr. Clin. North. Am.* 1996, 19 (3): 549–573.
87. Sharpley, A. et al.: Do patients with „pure“ chronic fatigue syndrome (neurasthenia) have abnormal sleep? *Psychosomatic Medicine* 1997, 59: 592–596.
88. Short, K.: Cognitive functioning in chronic fatigue syndrome and the role of depression, anxiety and fatigue. *J. Psychosom. Res.* 2002 Jun. 52 (6): 475–483.



89. Simpson, M.: A body with chronic fatigue syndrome as a battleground for the fight to separate from the mother. *J. Anal. Psychol.* 1997, 42: 201–216.
90. Smolík, P.: Duševní a behaviorální poruchy. Praha, Maxdorf s.r.o. 1996: 504 s.
91. Solomon, G. F. et al.: Shaking up immunity: psychological and immunologic changes after a natural disaster. *Psychosom. Medicine* 1997, 59: 143–142.
92. Song, C., Leonard, B. E.: Základy psychoneuroimunologie. Wiley 2000, Artax 2002.
93. Steidl, L. et al.: Chronický únavový syndrom. *Prakt. Lékař* 1993, 73: 134–139.
94. Stein, M. et al.: Depression, the immune system and health and illness. *Archives of General Psychiatry* 1991, 48: 171–177.
95. Steinberg, P. et al.: Double-blind placebo-controlled study of efficacy of oral terfenadin in the treatment of chronic fatigue syndrome. *Journal of Allergology and Clinical Immunology* 1996, 97: 119–126.
96. Strauss, S. E.: Chronic fatigue syndrome. In: *Harrison's Principles of Internal Medicine*, 1996: 2398–2400.
97. Strayer, D. R. et al.: A controlled clinical trial with specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. *Clinical Infect. Dis.* 1994, 18, suppl. 1: 88–95.
98. Suhadolnik, R. J. et al.: Changes in the 2-5A synthetase/Rnase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. *In Vivo* 1994, 8: 599–604.
99. Sundbom, E. et al.: Possible influence of defenses and negative life events on patients with chronic fatigue syndrome: a pilot study. *Psychol. Rep.* 2002 Dec. 91 (3 Pt 1): 963–978.

100. Swanink, C. M. A. et al.: Lymphocyte Subsets, Apoptosis and Cytokines in Patients with Chronic Fatigue Syndrome. *The Journal of Infectious Diseases* 1996, 173: 460–463.
101. Šebek, M.: Nemoc jako psychická realita. *Ami Report.* 1994, 7-8: 7–11.
102. Švestka, J.: SSRI – léky první volby. Praha, Maxdorf s.r.o. 1998, 160 s.
103. Švestka, J.: Vývoj antidepresiv od první k páté generaci. Praha, Psychiatrické centrum 1994, 96 s.
104. Švestka, J.: Psychofarmaka v klinické praxi. Praha, GRADA Publishing 1995, 249 s.
105. Taerk, G., Gnam, W.: A psychodynamic view of the chronic fatigue syndrome. The role of object relations in etiology and treatment. *General Hospital Psychiatry* 1994, 16: 319–325.
106. Taerk, G. S. et al.: Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). *Int. J. Psychiatry Medicine* 1987, 17: 49–56.
107. Taillefer, S. S. et al.: Psychological correlates of functional status in chronic fatigue syndrome. *J. Psychosom. Res.* 2002 Dec. 53 (6): 1097–1106.
108. Terman, M. et al.: Chronic fatigue syndrome and seasonal affective disorder: comorbidity, diagnostic overlap, and implications for treatment. *American Journal of Medicine* 1998, 105: 115–124.
109. Tondlová, H. et al.: Dosulepin in the treatment of depressive reactions in cancer patients (Preliminary report). *Activ. Nerv. Sup.*, Praha 1985, 27: 257–258.
110. Tsung-Yi Lin: Neurasthenia Revisited: Its Place in Modern Psychiatry. *Psychiatric Annals* 1992, 22: 173–185.
111. Vecchiet, J. et al.: Relationship between musculoskeletal



- symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. *Neurosci. Lett.* 2003 Jan. 2; 335 (3): 151–154.
112. Vercoulen, J. H. et al.: Randomised, double blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. *Lancet* 1996, 347: 858–861.
113. Vollmer-Conna, U. et al.: Chronic fatigue syndrome: an immunological perspective. *Australian-N. Z. Journal of Psychiatry* 1998, 32: 523–527.
114. Vollmer-Conna, U. et al.: Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. *Am. Journal of Medicine* 1997, 103: 38–43.
115. Vrabel, J. et al.: Chronický únavový syndrom (CFS). *Prakt. lékař* 1996, 76: 534–538.
116. Wessely, S.: Old wine in new bottles: neurasthenia and ME. *Psychologic Medicine* 1990, 20: 146–150.
117. Wessely, S. and Powell, R.: Fatigue syndromes: a comparison of chronic „postviral fatigue“ with neuromuscular and affective disorders. *Journal of Neurology, Neurosurgery and Psychiatry* 1989, 52: 940–948.
118. Wilson, A. et al.: The Treatment of Chronic Fatigue Syndrome: Science and Speculation. *The American Journal of Medicine* 1994, 96: 544–550.
119. Ware, N. C., Kleinman, A.: Depression in Neurasthenia and Chronic Fatigue Syndrome. *Psychiatric Annals* 1992, 22: 202–208.
120. Williams, G.: Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. *Eur. J. Clin. Invest.* 2002 Nov; 32 (11): 831–837.

121. Yanping, Z. et al.: Neurasthenia in Chinese Students and Visiting Scholars in the United States. *Psychiatric Annals* 1992, 22: 194–198.
122. Young, A. H., et al.: Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). *Biological Psychiatry* 1998, 43: 236–237.

